Aurinia (AUPH) Q2 Revenue Jumps 22%
Aurinia Pharmaceuticals (NASDAQ:AUPH), a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue (GAAP) came in at $70.0 million, which exceeded analyst expectations of $63.8 million by 9.7% (GAAP). Diluted earnings per share (GAAP) were $0.16, just ahead of the $0.15 GAAP estimate, and a large jump from $0.01 in the prior year (GAAP, Q2 2024). Management also increased its full-year revenue and net product sales forecasts, signaling confidence in ongoing business trends. The quarter continued a positive stretch for the company, showing business momentum and disciplined cost control.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Aurinia Pharmaceuticals develops and markets therapies for autoimmune diseases, with a primary focus on lupus nephritis, a severe kidney complication commonly resulting from systemic lupus erythematosus. Its main commercial product is LUPKYNIS, an oral therapy designed for adults with active lupus nephritis.
Source Fool.com
